Trding- I think you nailed it. The last couple yea

Trding- I think you nailed it. The last couple years it’s been hard to see the end game for the company bc they continue to pivot and raise money. This company was easier to digest as an investor when it was just an HIV company. Remember when it was just HIV we at least had an end in sight. Since than we have added GvHD which has also been delayed without much communication. Then RP joined and it basically became an oncology play, but can’t seem to find anyone to inject (I know this has more to do with trial logistics than patients, but the company hasn’t done a great job in communicating that). While everything we have added potentially provides substantially more value to the company it also adds uncertainty about how, when, and how much it will take for this to play out.

If we had stayed just HIV, I strongly believe we would have had a BO by now. But we are just starting to understand the potential of this drug, which does three things: adds an unknown amount of time before BO, makes it incredibly hard to value and incredibly risky for a BP to buy it at full potential value. As soon as we have some certainty around financing as well as mono/GvHD/TNBC we will hopefully see SP.

I included mono not bc we don’t have enough science. I think we do. But if we are missing anything I think it is that we may be underestimating how difficult and how long it will take for Leronlimab to disrupt a well established, trusted and effective ecosystem that HAART has monopolizes since the early 90s. Even with a better drug.